A Phase II, Multi-center, Open-label, Dose-finding Study to Evaluate Safety, Efficacy and Tolerability of Subcutaneously (SC) Administered rAvPAL-PEG in Patients With PKU for 24 Weeks
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2015
At a glance
- Drugs Pegvaliase (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 24 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
- 08 Apr 2015 Planned primary completion date changed from 1 Mar 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.